1027 related articles for article (PubMed ID: 31623665)
21. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
Fukushima Y; Someya M; Nakata K; Hori M; Kitagawa M; Hasegawa T; Tsuchiya T; Gocho T; Ikeda H; Hirohashi Y; Torigoe T; Sugita S; Hasegawa T; Himi T; Sakata KI
Radiother Oncol; 2018 Nov; 129(2):409-414. PubMed ID: 30249348
[TBL] [Abstract][Full Text] [Related]
22. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment.
Cramer JD; Ferris RL; Kim S; Duvvuri U
Oral Oncol; 2018 Dec; 87():170-176. PubMed ID: 30527235
[TBL] [Abstract][Full Text] [Related]
23. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
24. Immune cell infiltration in head and neck squamous cell carcinoma and patient outcome: a retrospective study.
Schneider K; Marbaix E; Bouzin C; Hamoir M; Mahy P; Bol V; Grégoire V
Acta Oncol; 2018 Sep; 57(9):1165-1172. PubMed ID: 29493423
[TBL] [Abstract][Full Text] [Related]
25. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
[TBL] [Abstract][Full Text] [Related]
26. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).
Balermpas P; Rödel F; Rödel C; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Gkika E; Stuschke M; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Stangl S; Belka C; Pigorsch S; Multhoff G; Combs SE; Mönnich D; Zips D; Fokas E
Int J Cancer; 2016 Jan; 138(1):171-81. PubMed ID: 26178914
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of tumour-infiltrating lymphocytes as a prognostic factor in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Ruangritchankul K; Sandison A; Warburton F; Guerrero-Urbano T; Reis Ferreira M; Lei M; Thavaraj S
Histopathology; 2019 Jul; 75(1):146-150. PubMed ID: 31144335
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
29. CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma.
Wagner S; Wittekindt C; Reuschenbach M; Hennig B; Thevarajah M; Würdemann N; Prigge ES; von Knebel Doeberitz M; Dreyer T; Gattenlöhner S; Klussmann JP
Int J Cancer; 2016 May; 138(9):2263-73. PubMed ID: 26662627
[TBL] [Abstract][Full Text] [Related]
30. Impact of HPV Infection on the Immune System in Oropharyngeal and Non-Oropharyngeal Squamous Cell Carcinoma: A Systematic Review.
Lechien JR; Seminerio I; Descamps G; Mat Q; Mouawad F; Hans S; Julieron M; Dequanter D; Vanderhaegen T; Journe F; Saussez S
Cells; 2019 Sep; 8(9):. PubMed ID: 31510065
[TBL] [Abstract][Full Text] [Related]
31. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
[TBL] [Abstract][Full Text] [Related]
32. Fewer tumour-specific PD-1
Xu K; Fu Y; Han Y; Xia R; Xu S; Duan S; Zhang Z; Li J
Br J Cancer; 2020 Sep; 123(6):932-941. PubMed ID: 32616847
[TBL] [Abstract][Full Text] [Related]
33. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
[TBL] [Abstract][Full Text] [Related]
34. Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Brcic I; Gallob M; Schwantzer G; Zrnc T; Weiland T; Thurnher D; Wolf A; Brcic L
Oral Oncol; 2020 Jul; 106():104719. PubMed ID: 32335324
[TBL] [Abstract][Full Text] [Related]
35. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
36. T cell fraction impacts oncologic outcomes in human papillomavirus associated oropharyngeal squamous cell carcinoma.
Van Abel KM; Routman DM; Moore EJ; Ma DJ; Yin LX; Fields PA; Schofield M; Bartemes KR; Chatzopoulos K; Price DL; Janus JR; Kasperbauer JL; Price KA; Chintakuntlawar AV; Neben-Wittich MA; Foote RL; Garcia JJ
Oral Oncol; 2020 Dec; 111():104894. PubMed ID: 32712575
[TBL] [Abstract][Full Text] [Related]
37. Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable.
Ren J; Xu W; Su J; Ren X; Cheng D; Chen Z; Bender N; Mirshams M; Habbous S; de Almeida JR; Perez-Ordonez B; Goldstein DP; Wang JR; Bratman SV; Huang SH; Jang R; Zhao Y; Waterboer T; Hung RJ; Liu G
Int J Cancer; 2020 Apr; 146(8):2166-2174. PubMed ID: 31269236
[TBL] [Abstract][Full Text] [Related]
38. Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis of CD8
Sivars L; Landin D; Grün N; Vlastos A; Marklund L; Nordemar S; Ramqvist T; Munck-Wikland E; Näsman A; Dalianis T
Anticancer Res; 2017 Feb; 37(2):665-673. PubMed ID: 28179315
[TBL] [Abstract][Full Text] [Related]
39. The interplay between HPV and host immunity in head and neck squamous cell carcinoma.
Andersen AS; Koldjaer Sølling AS; Ovesen T; Rusan M
Int J Cancer; 2014 Jun; 134(12):2755-63. PubMed ID: 23913554
[TBL] [Abstract][Full Text] [Related]
40. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
Heusinkveld M; Goedemans R; Briet RJ; Gelderblom H; Nortier JW; Gorter A; Smit VT; Langeveld AP; Jansen JC; van der Burg SH
Int J Cancer; 2012 Jul; 131(2):E74-85. PubMed ID: 22020783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
